PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|April 27, 2015
Pharma's $462 Billion of M&As Since Jan 2014
Author(s)News Update
April 27, 2015.
Advertisement
Today's Financial Times (FT) reports
that, since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions - greater than the gross domestic product of Austria. In a piece entitled "No end in sight to wave of pharma dealmaking", and following the latest advances by Teva to make a bid for Mylan, Andrew Ward asks "What is driving the frenzy?" According to Jeremy Levin, former chief executive of Teva, the most impetus has been financial rather than strategic. For more on this story,
click here
.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5